
Brookfield, CDPQ Complete $1.34B Acquisition of Antylia Scientific, Expanding Life Sciences Investment
Brookfield Asset Management and Caisse de dépôt et placement du Québec (CDPQ) have completed the acquisition of Antylia Scientific for approximately $1.34 billion, concluding a decade-long ownership by private equity firm GTCR. The transaction marks another significant industrial investment for Brookfield, following its $1.7 billion acquisition of Chemelex earlier this year.
Based in Vernon Hills, Illinois, Antylia Scientific provides essential consumables and testing equipment for diagnostic, environmental, and life sciences laboratories. Since GTCR’s initial acquisition in 2014—then known as Cole-Parmer Instrument Company in a carve-out from Thermo Fisher Scientific—Antylia has undergone substantial transformation. GTCR supported 15 strategic add-on acquisitions and divested the Masterflex bioprocessing segment in a $2.9 billion sale to Avantor in 2021.
Brookfield Private Equity Group CEO Anuj Ranjan noted plans to enhance Antylia’s growth through improvements in commercial strategy and procurement. CDPQ’s Martin Longchamps emphasized the company’s role in supporting mission-critical industries.
Goldman Sachs and Jefferies advised Antylia on the deal, with legal counsel from Kirkland & Ellis. GTCR was advised by J.P. Morgan Securities.